DK648487A - Spiro-substituerede glutaramid-derivater og deres medicinske anvendelse samt farmaceutiske praeparater indeholdende disse forbindelser - Google Patents

Spiro-substituerede glutaramid-derivater og deres medicinske anvendelse samt farmaceutiske praeparater indeholdende disse forbindelser

Info

Publication number
DK648487A
DK648487A DK648487A DK648487A DK648487A DK 648487 A DK648487 A DK 648487A DK 648487 A DK648487 A DK 648487A DK 648487 A DK648487 A DK 648487A DK 648487 A DK648487 A DK 648487A
Authority
DK
Denmark
Prior art keywords
spiro
compounds
pharmaceutical preparations
medical use
preparations containing
Prior art date
Application number
DK648487A
Other languages
English (en)
Other versions
DK648487D0 (da
DK174922B1 (da
Inventor
Ian Thomson Barnish
John Christopher Danilewicz
Keith James
Gillian Mary Ryder Samuels
Nicholas Kenneth Terrett
Martin James Wythes
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868629663A external-priority patent/GB8629663D0/en
Priority claimed from GB878715722A external-priority patent/GB8715722D0/en
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of DK648487D0 publication Critical patent/DK648487D0/da
Publication of DK648487A publication Critical patent/DK648487A/da
Application granted granted Critical
Publication of DK174922B1 publication Critical patent/DK174922B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/61—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/04—Seven-membered rings not condensed with other rings
    • C07D321/08—1,4-Dioxepines; Hydrogenated 1,4-dioxepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK198706484A 1986-12-11 1987-12-10 Spiro-substituerede glutaramid-derivater, disse forbindelser til medicinsk anvendelse samt farmaceutiske præparater indeholdende forbindelserne DK174922B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8629663 1986-12-11
GB868629663A GB8629663D0 (en) 1986-12-11 1986-12-11 Therapeutic agents
GB8715722 1987-07-03
GB878715722A GB8715722D0 (en) 1987-07-03 1987-07-03 Therapeutic agents

Publications (3)

Publication Number Publication Date
DK648487D0 DK648487D0 (da) 1987-12-10
DK648487A true DK648487A (da) 1988-08-19
DK174922B1 DK174922B1 (da) 2004-02-23

Family

ID=26291684

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198706484A DK174922B1 (da) 1986-12-11 1987-12-10 Spiro-substituerede glutaramid-derivater, disse forbindelser til medicinsk anvendelse samt farmaceutiske præparater indeholdende forbindelserne

Country Status (25)

Country Link
US (1) US5030654A (da)
EP (1) EP0274234B1 (da)
KR (2) KR880007441A (da)
CN (1) CN1016778B (da)
AU (1) AU595082B2 (da)
CA (1) CA1328264C (da)
CY (1) CY1723A (da)
DE (1) DE3772950D1 (da)
DK (1) DK174922B1 (da)
EG (1) EG18361A (da)
ES (1) ES2031523T3 (da)
FI (1) FI94336C (da)
GR (1) GR3002739T3 (da)
HK (1) HK65893A (da)
HU (1) HU202482B (da)
IE (1) IE60304B1 (da)
IL (1) IL84757A (da)
MY (1) MY100740A (da)
NO (1) NO174385C (da)
NZ (1) NZ222848A (da)
PH (1) PH25058A (da)
PL (1) PL150420B1 (da)
PT (1) PT86316B (da)
SG (1) SG50593G (da)
YU (1) YU47970B (da)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337400C (en) * 1987-06-08 1995-10-24 Norma G. Delaney Inhibitors of neutral endopeptidase
GB8811873D0 (en) * 1988-05-19 1988-06-22 Pfizer Ltd Therapeutic agents
GB8812597D0 (en) * 1988-05-27 1988-06-29 Pfizer Ltd Therapeutic agents
GB8820844D0 (en) * 1988-09-05 1988-10-05 Pfizer Ltd Therapeutic agents
GB8903740D0 (en) * 1989-02-18 1989-04-05 Pfizer Ltd Therapeutic agents
GB8907704D0 (en) * 1989-04-05 1989-05-17 Pfizer Ltd Preparation of glutaric acid derivatives
US5260467A (en) * 1989-11-16 1993-11-09 Pfizer Inc. Glutaric acid derivatives and preparation thereof
GB8925933D0 (en) * 1989-11-16 1990-01-04 Pfizer Ltd Glutaric acid derivatives and preparation thereof
US5157138A (en) * 1989-11-16 1992-10-20 Pfizer, Inc. Glutaric acid derivatives and preparation thereof
GB8926063D0 (en) * 1989-11-17 1990-01-10 Pfizer Ltd Therapeutic agents
US5389610A (en) * 1989-11-21 1995-02-14 Schering Corporation Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors
AU7168091A (en) * 1989-12-22 1991-07-24 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors
GB9000725D0 (en) * 1990-01-12 1990-03-14 Pfizer Ltd Therapeutic agents
GB9004260D0 (en) * 1990-02-26 1990-04-18 Pfizer Ltd Therapeutic agents
US5075302A (en) * 1990-03-09 1991-12-24 Schering Corporation Mercaptoacyl aminolactam endopeptidase inhibitors
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
US5264420A (en) * 1990-09-27 1993-11-23 Merck & Co., Inc. Fibrinogen receptor antagonists
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
GB9103454D0 (en) * 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5252601A (en) * 1991-05-03 1993-10-12 Merrell Dow Pharmaceuticals Inc. 2-mercaptomethylene-tetrahydronaphthalene and indane-2-carboxamide derivatives as enkephalinase inhibitors
FI934894A0 (fi) * 1991-05-07 1993-11-05 Merck & Co Inc Fibrinogenreceptorantagonister
US5321034A (en) * 1991-05-07 1994-06-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5272158A (en) * 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
US5416099A (en) * 1991-10-29 1995-05-16 Merck & Co., Inc. Fibrinogen receptor antagonists
US5389631A (en) * 1991-10-29 1995-02-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5298492A (en) * 1992-08-04 1994-03-29 Schering Corporation Diamino acid derivatives as antihypertensives
US5208236A (en) * 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use
US5629343A (en) * 1992-10-02 1997-05-13 Merck & Co., Inc. N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents
WO1994008962A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
US5358956A (en) * 1992-10-14 1994-10-25 Merck & Co., Inc. Fibrinogen receptor antagonists
US6090785A (en) * 1992-10-15 2000-07-18 Merck & Co., Inc. Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents
WO1994012169A1 (en) * 1992-11-25 1994-06-09 Merck & Co., Inc. Carboxy-peptidyl derivatives as antidegenerative active agents
WO1994012181A1 (en) * 1992-12-01 1994-06-09 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH06199850A (ja) * 1992-12-28 1994-07-19 Tanabe Seiyaku Co Ltd インドール含有ペプチド及びその製法
US5441952A (en) * 1993-04-05 1995-08-15 Merck & Co., Inc. Fibrinogen receptor antagonists
US5334596A (en) * 1993-05-11 1994-08-02 Merck & Co., Inc. Fibrinogen receptor antagonists
US5397791A (en) * 1993-08-09 1995-03-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5821241A (en) * 1994-02-22 1998-10-13 Merck & Co., Inc. Fibrinogen receptor antagonists
US5719144A (en) * 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
US5684152A (en) * 1995-09-28 1997-11-04 Merck & Co., Inc. Preparation of carboxyalkyl derivatives as inhibitors of matrix metalloproteinases
US5852045A (en) * 1995-10-19 1998-12-22 Merck & Co., Inc. Fibrinogen receptor antagonists
US5789421A (en) * 1995-10-26 1998-08-04 Merck & Co., Inc. Fibrinogen receptor antagonist
US5780480A (en) * 1996-02-28 1998-07-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5889023A (en) * 1996-05-10 1999-03-30 Merck & Co., Inc. Fibrinogen receptor antagonist
US5981584A (en) * 1997-02-06 1999-11-09 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US6043389A (en) 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
RU2245147C2 (ru) * 1999-03-29 2005-01-27 Бристол-Маерс Сквибб Компани Применение ингибитора вазопептидазы для лечения стенокардии
IL139457A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US6660756B2 (en) 2001-03-28 2003-12-09 Pfizer Inc. N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
SK14102003A3 (sk) * 2001-05-18 2004-08-03 Solvay Pharmaceuticals Gmbh Použitie zlúčenín s kombinovanou inhibičnou aktivitou k NEP/MP pri príprave liečiv
US20070197552A1 (en) * 2002-01-11 2007-08-23 Novo Nordisk A/S Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
WO2003057200A2 (en) * 2002-01-11 2003-07-17 Novo Nordisk A/S Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
JO2479B1 (en) * 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
US7045653B2 (en) 2002-12-23 2006-05-16 Pfizer, Inc. Pharmaceuticals
TW200838501A (en) * 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
EP2200975A1 (en) 2007-09-07 2010-06-30 Theravance, Inc. Dual-acting antihypertensive agents
US8212052B2 (en) 2007-12-11 2012-07-03 Theravance, Inc. Dual-acting benzoimidazole antihypertensive agents
JP2011518884A (ja) 2008-04-29 2011-06-30 セラヴァンス， インコーポレーテッド 二重活性抗高血圧剤
US7863309B2 (en) 2008-07-24 2011-01-04 Theravance, Inc. Dual-acting antihypertensive agents
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
JP5420761B2 (ja) * 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
WO2011005674A1 (en) 2009-07-07 2011-01-13 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
WO2011011232A1 (en) 2009-07-22 2011-01-27 Theravance, Inc. Dual-acting oxazole antihypertensive agents
US8481549B2 (en) * 2010-01-19 2013-07-09 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
NZ611528A (en) 2010-12-15 2015-06-26 Theravance Biopharma R & D Ip Llc Neprilysin inhibitors
US8586536B2 (en) 2010-12-15 2013-11-19 Theravance, Inc. Neprilysin inhibitors
CA2825737C (en) 2011-02-17 2018-11-13 Theravance, Inc. Substituted aminobutyric derivatives as neprilysin inhibitors
US8449890B2 (en) 2011-02-17 2013-05-28 Theravance, Inc. Neprilysin inhibitors
US8513244B2 (en) 2011-05-31 2013-08-20 Theravance, Inc. Neprilysin inhibitors
CA2835220A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
WO2012166389A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
US9045443B2 (en) 2012-05-31 2015-06-02 Theravance Biopharma R&D Ip, Llc Nitric oxide donor neprilysin inhibitors
JP6162230B2 (ja) 2012-06-08 2017-07-12 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
EP2858650B1 (en) 2012-06-08 2018-11-14 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
AU2013299642B2 (en) 2012-08-08 2017-06-08 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
WO2014127331A1 (en) 2013-02-17 2014-08-21 Intra-Cellular Therapies, Inc. Novel uses
EP2964616B1 (en) 2013-03-05 2017-05-03 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
US9585882B2 (en) 2014-01-30 2017-03-07 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
EP3099678B1 (en) 2014-01-30 2018-12-12 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
DK3177627T3 (da) 2014-08-07 2019-10-21 Intra Cellular Therapies Inc Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on-derivater med pde1-hæmmende aktivitet
ES2923002T3 (es) 2015-02-11 2022-09-22 Theravance Biopharma R&D Ip Llc Acido (2S,4R)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxailamino)-2-hidroximetil-2-metilpentanoico como inhibidor de la neprilisina
RU2715241C2 (ru) 2015-02-19 2020-02-26 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи (2r,4r)-5-(5′-хлор-2′-фторбифенил-4-ил)-2-гидрокси-4-[(5-метилоксазол-2-карбонил)амино]пентановая кислота
PT3408260T (pt) 2016-03-08 2021-07-23 Theravance Biopharma R&D Ip Llc Ácido (2s,4r)-5-(5¿-cloro-2¿-fluoro-[1,1¿-bifenil]-4-il)-2- (etoximetil)-4-(3-hidroxi-isoxazole-5-carboxamido)-2- metilpentanoico cristalino e suas utilizações
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981915A (en) * 1971-12-17 1976-09-21 American Home Products Corporation Amides of 1-aminocyclopentane carboxylic acid
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
JPS61502468A (ja) * 1984-06-08 1986-10-30 チバ・ガイギ−・アクチェンゲゼルシャフト Ｎ−置換ブチルアミド誘導体
GB2167748A (en) * 1984-11-23 1986-06-04 Squibb & Sons Inc Acylamino hydroxyalkanoyl amino and imino acids and esters
EP0225292A3 (en) * 1985-12-06 1988-11-30 Ciba-Geigy Ag Certain n-substituted butyramide derivatives
US4749688A (en) * 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension

Also Published As

Publication number Publication date
CA1328264C (en) 1994-04-05
KR910003335B1 (ko) 1991-05-27
PL150420B1 (en) 1990-05-31
HU202482B (en) 1991-03-28
IE60304B1 (en) 1994-06-29
FI94336C (fi) 1995-08-25
EP0274234B1 (en) 1991-09-11
PH25058A (en) 1991-01-28
CN87107371A (zh) 1988-07-06
CN1016778B (zh) 1992-05-27
NO875169D0 (no) 1987-12-10
YU223987A (en) 1989-02-28
FI875413A0 (fi) 1987-12-09
PL269336A1 (en) 1988-12-08
GR3002739T3 (en) 1993-01-25
ES2031523T3 (es) 1992-12-16
HK65893A (en) 1993-07-16
IL84757A (en) 1992-02-16
EP0274234A3 (en) 1988-10-19
CY1723A (en) 1994-05-06
AU8240787A (en) 1988-07-07
DK648487D0 (da) 1987-12-10
NO174385B (no) 1994-01-17
FI94336B (fi) 1995-05-15
EG18361A (en) 1992-12-30
NZ222848A (en) 1989-10-27
PT86316B (pt) 1990-11-07
IL84757A0 (en) 1988-05-31
SG50593G (en) 1993-07-09
US5030654A (en) 1991-07-09
MY100740A (en) 1991-01-31
FI875413A7 (fi) 1988-06-12
PT86316A (en) 1988-01-01
YU47970B (sh) 1996-08-13
DE3772950D1 (de) 1991-10-17
EP0274234A2 (en) 1988-07-13
NO875169L (no) 1988-06-13
KR880007441A (ko) 1988-08-27
HUT45487A (en) 1988-07-28
IE873355L (en) 1988-06-11
DK174922B1 (da) 2004-02-23
NO174385C (no) 1994-04-27
AU595082B2 (en) 1990-03-22

Similar Documents

Publication Publication Date Title
DK648487D0 (da) Spiro-substituerede glutaramid-derivater og deres medicinske anvendelse samt farmaceutiske praeparater indeholdende disse forbindelser
DK108388A (da) Piperazinylalkylheterocycliske forbindelser og farmaceutiske praeparater indeholdende disse
DK164868C (da) Imidazooe4,5-baaquinolin-2-on-derivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende disse
DK128688D0 (da) Thiazolderivater og fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende derivaterne
NO862095L (no) Farmasoeytiske preparater inneholdende vevsplasmnogenaktivitator og fremgangsmaate for deres fremstilling.
DK162986C (da) 4-substituerede 2-amino-5-hydroxypyrimidin-forbindelser og farmaceutiske praeparater indeholdende disse
DK219387D0 (da) Aminothiazol- og aminooxazolderivater, fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende disse
DK553988D0 (da) 4-aminopyridin-derivater og farmaceutiske praeparater indeholdende disse
DK163990C (da) Oxindol-3-carboxamid-derivater og farmaceutiske praeparater indeholdende disse
DK166355C (da) Adenosin-derivater samt farmaceutiske praeparater indeholdende saadanne derivater
DK116989A (da) Polypeptider samt farmaceutiske praeparater indeholdende disse forbindelser
DK78888D0 (da) Arylpiperazinylalkylenphenyl-heterocycliske forbindelser og farmaceutiske praeparater indeholdende disse
DK143188A (da) Farmaceutiske praeparater indeholdende pyranoquinolinforbindelser samt deres anvendelse
DK477685A (da) Peptidsubstituerede heterocycliske forbindelser og anvendelse deraf som immunostimulerende eller antiinfektive forbindelser samt farmaceutiske praeparater
DK160944C (da) Modificerede beta2-mikroglobuliner og farmaceutiske praeparater indeholdende disse
DK269289A (da) Cyklopentanderivater og farmaceutiske praeparater indeholdende saadanne forbindelser
DK4487D0 (da) Heterocycliske forbindelser og farmaceutiske praeparater indeholdende disse
DK191086D0 (da) Benzisoselenazolonylderivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende disse
DK135789A (da) 19-thiosubstituerede delta4-androstenderivater samt farmaceutisk praeparat indeholdende disse
DK449989A (da) Quinolinderivater, deres fremstilling og laegemidler indeholdende disse derivater
DK162092C (da) Basisk substituerede 3-phenyl-quinolin-2-on-derivater, deres fremstilling og anvendelse samt laegemiddel indeholdende disse derivater
DK488688D0 (da) Azolidindion-derivater og farmaceutiske praeparater indeholdende disse
DK352586D0 (da) 11-methylen-oestr-15-ener, fremgangsmaader til deres fremstilling og farmaceutiske praeparater indeholdende disse oestrener
DK213988A (da) Dihydropyridinforbindelser samt medisinsk anvendelse af disse og beslaegtede forbindelser og farmaceutiske praeparater indholdende disse.
DK511687A (da) Farmaceutisk praeparat, samt fremstilling og anvendelse heraf

Legal Events

Date Code Title Description
PBP Patent lapsed

Country of ref document: DK